Profile data is unavailable for this security.
About the company
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.
- Revenue in USD (TTM)217.77m
- Net income in USD-438.86m
- Incorporated2019
- Employees550.00
- LocationBridgeBio Pharma Inc3160 Porter Dr., Suite 250PALO ALTO 94304United StatesUSA
- Phone+1 (650) 391-9740
- Fax+1 (302) 655-5049
- Websitehttps://bridgebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals Inc | 2.68bn | -184.45m | 2.58bn | 7.70k | -- | -- | 31.99 | 0.9608 | -0.6835 | -0.6835 | 9.08 | -0.3016 | 0.75 | 2.96 | 3.73 | 348,106.50 | -4.10 | -4.80 | -5.45 | -5.93 | 35.34 | 34.76 | -5.46 | -9.00 | 0.8372 | 1.26 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Vericel Corp | 226.84m | 3.55m | 2.80bn | 314.00 | 733.07 | 10.85 | 314.61 | 12.34 | 0.0774 | 0.0774 | 4.69 | 5.23 | 0.6403 | 4.56 | 5.14 | 722,433.10 | 1.00 | -3.07 | 1.12 | -3.50 | 71.47 | 67.87 | 1.56 | -4.49 | 4.23 | -- | 0.0009 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| PTC Therapeutics, Inc. | 900.66m | -453.20m | 3.31bn | 988.00 | -- | -- | -- | 3.67 | -5.94 | -5.94 | 11.79 | -13.70 | 0.5807 | 1.97 | 4.93 | 911,603.30 | -29.22 | -26.71 | -45.34 | -33.46 | 92.20 | 93.94 | -50.32 | -83.80 | 2.04 | -0.7925 | 1.79 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| Apellis Pharmaceuticals Inc | 715.22m | -250.10m | 3.45bn | 702.00 | -- | 14.29 | -- | 4.83 | -2.04 | -2.04 | 5.81 | 1.94 | 0.8316 | 0.8814 | 3.19 | 1,018,828.00 | -29.08 | -73.88 | -37.24 | -90.03 | 86.47 | -- | -34.97 | -326.49 | 3.73 | -9.20 | 0.656 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Perrigo Company PLC | 4.39bn | -146.90m | 3.69bn | 9.14k | -- | 0.8096 | 20.01 | 0.8412 | -1.07 | -1.17 | 32.07 | 33.45 | 0.40 | 2.46 | 5.58 | 480,525.20 | -1.34 | -0.1148 | -1.51 | -0.1315 | 36.07 | 35.28 | -3.34 | -0.2985 | 1.77 | 1.26 | 0.51 | -- | 4.58 | -0.3238 | 96.64 | -- | -5.95 | 7.52 |
| Organon & Co | 6.41bn | 1.30bn | 3.83bn | 10.00k | 2.95 | 7.78 | 2.46 | 0.5983 | 5.04 | 5.04 | 24.81 | 1.91 | 0.5394 | 2.08 | 3.85 | 640,900.00 | 10.95 | 16.53 | 14.08 | 20.97 | 58.26 | 65.12 | 20.30 | 26.79 | 1.21 | 2.73 | 0.9467 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.91 | -- |
| Prestige Consumer Healthcare Inc | 1.11bn | 205.95m | 4.16bn | 570.00 | 20.50 | 2.40 | 17.50 | 3.74 | 4.11 | 4.11 | 22.14 | 35.03 | 0.334 | 3.13 | 6.90 | 1,948,525.00 | 6.19 | 3.69 | 6.42 | 3.84 | 55.21 | 56.79 | 18.54 | 12.19 | 2.10 | 5.68 | 0.3779 | 0.00 | -0.21 | 2.89 | 354.34 | -- | -1.84 | -- |
| BridgeBio Pharma Inc | 217.77m | -438.86m | 4.37bn | 550.00 | -- | -- | -- | 20.07 | -2.41 | -2.41 | 1.19 | -6.51 | 0.33 | -- | -- | 395,936.40 | -67.62 | -72.44 | -85.06 | -89.72 | 98.90 | 94.41 | -204.94 | -1,225.66 | -- | -9.40 | 3.43 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Axsome Therapeutics Inc | 338.46m | -310.96m | 4.71bn | 545.00 | -- | 51.20 | -- | 13.93 | -6.54 | -6.54 | 7.11 | 1.92 | 0.5824 | 2.49 | 3.34 | 621,022.00 | -53.51 | -64.55 | -73.04 | -82.23 | 91.09 | -- | -91.87 | -227.05 | 2.37 | -60.51 | 0.6648 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| ADMA Biologics Inc | 382.81m | 68.13m | 5.04bn | 624.00 | 77.08 | 21.71 | 65.95 | 13.15 | 0.2763 | 0.2763 | 1.61 | 0.981 | 1.04 | 1.17 | 9.40 | 613,475.40 | 18.42 | -24.80 | 20.87 | -28.00 | 48.93 | 17.40 | 17.80 | -51.31 | 3.26 | 7.58 | 0.3041 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Avidity Biosciences Inc | 10.12m | -280.49m | 5.08bn | 253.00 | -- | 3.37 | -- | 501.91 | -2.90 | -2.90 | 0.1028 | 12.64 | 0.0091 | -- | -- | 39,988.14 | -25.34 | -31.61 | -27.05 | -34.45 | -- | -- | -2,772.45 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Halozyme Therapeutics, Inc. | 947.36m | 392.47m | 5.81bn | 373.00 | 15.12 | 12.84 | 12.26 | 6.14 | 3.02 | 3.02 | 7.30 | 3.56 | 0.4724 | 1.30 | 3.77 | 2,539,826.00 | 19.57 | 18.22 | 20.73 | 21.97 | 82.09 | 79.05 | 41.43 | 39.36 | 9.15 | -- | 0.7687 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Corcept Therapeutics Incorporated | 628.56m | 141.82m | 5.86bn | 352.00 | 44.04 | 9.14 | 40.98 | 9.32 | 1.27 | 1.27 | 5.64 | 6.12 | 0.9121 | 1.26 | 13.32 | 1,785,668.00 | 20.58 | 21.17 | 25.10 | 23.85 | 98.44 | 98.52 | 22.56 | 27.23 | 3.64 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
Data as of Nov 22 2024. Currency figures normalised to BridgeBio Pharma Inc's reporting currency: US Dollar USD
42.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Viking Global Investors LPas of 30 Sep 2024 | 25.12m | 13.36% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 13.87m | 7.37% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 10.71m | 5.70% |
| Aisling Capital Management LPas of 30 Sep 2024 | 6.07m | 3.23% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 5.96m | 3.17% |
| Janus Henderson Investors US LLCas of 30 Sep 2024 | 4.76m | 2.53% |
| Laurion Capital Management LPas of 30 Sep 2024 | 3.89m | 2.07% |
| Geode Capital Management LLCas of 30 Sep 2024 | 3.41m | 1.82% |
| AllianceBernstein LPas of 30 Sep 2024 | 2.83m | 1.50% |
| Pictet Asset Management SAas of 30 Sep 2024 | 2.80m | 1.49% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
